Giuseppe Colantuoni
- Oncology top 10%
- Cancer Treatment and Pharmacology 10
- Lung Cancer Research Studies 6
- HER2/EGFR in Cancer Research 6
- Colorectal Cancer Treatments and Studies 5
- Peptidase Inhibition and Analysis 3
-
- Lung Cancer Treatments and Mutations 16
- Advanced Breast Cancer Therapies 3
-
- Hepatocellular Carcinoma Treatment and Prognosis 3
Giuseppe Colantuoni
28 papers receiving 502 citations
Peers
Comparison fields: 5 of 61
- Oncology 317
- Cancer Research 86
- Pulmonary and Respiratory Medicine 182
- Hepatology 23
- Molecular Biology 185
Countries citing papers authored by Giuseppe Colantuoni
This map shows the geographic impact of Giuseppe Colantuoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Colantuoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Colantuoni more than expected).
Fields of papers citing papers by Giuseppe Colantuoni
This network shows the impact of papers produced by Giuseppe Colantuoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Colantuoni. The network helps show where Giuseppe Colantuoni may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Giuseppe Colantuoni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 8 | |
| 2 | 2019 | 3 | |
| 3 | 2014 | 1 | |
| 4 | 2011 | 21 | |
| 5 | 2009 | 22 | |
| 6 | 2009 | 12 | |
| 7 | 2009 | 58 | |
| 8 | 2008 | 7 | |
| 9 | 2007 | 9 | |
| 10 | 2006 | 16 | |
| 11 | 2006 | 70 | |
| 12 | 2005 | 16 | |
| 13 | 2005 | 6 | |
| 14 | Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. | 2004 | 3 |
| 15 | 2004 | 17 | |
| 16 | 2004 | 34 | |
| 17 | 2003 | 1 | |
| 18 | Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. | 2003 | 28 |
| 19 | Oral cytotoxic drugs. | 2002 | 3 |
| 20 | 2002 | 2 |
About Giuseppe Colantuoni
Giuseppe Colantuoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 28 papers that have together received 509 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), Cancer Treatment and Pharmacology (10 papers), Lung Cancer Research Studies (6 papers), HER2/EGFR in Cancer Research (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Advanced Breast Cancer Therapies (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Oncology (317 citations), Cancer Research (86 citations) and Pulmonary and Respiratory Medicine (182 citations). Giuseppe Colantuoni has collaborated with scholars based in Italy and United Kingdom. Frequent co-authors include Antônio Rossi, Paolo Maione, Cesare Gridelli, Ciro Guerriero, Dario Nicolella, Carmine Ferrara, Filomena Del Gaizo, Emanuela Rossi, Fortunato Ciardiello and Sabino De Placido. Their work appears in journals such as The Oncologist, Journal of Clinical Oncology, Annals of Oncology, Critical Reviews in Oncology/Hematology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.